Navigation Links
BioCryst Reports Fourth Quarter and Full Year 2009 Financial Results and Provides Corporate Update
Date:2/4/2010

inties.  Given these uncertainties, you should not place undue reliance on these forward-looking statements.  Some of the factors that could affect the forward-looking statements contained herein include: that to the extent peramivir is used as a treatment for H1N1 flu (or other strains of flu), there can be no assurance that it will prove effective; that HHS may further condition, reduce or eliminate future funding of the peramivir program; that ongoing peramivir clinical trials or our peramivir program in general may not be successful; that the pivotal trial with forodesine in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint; that development and commercialization of forodesine  in CTCL may not be successful; that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed; that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates; that our product candidates may not receive required regulatory clearances from the FDA; that ongoing and future pre-clinical and clinical development may not have positive results; that we or our licensees may not be able to continue future development of our current and future development programs; that our development programs may never result in future product, license or royalty payments being received by BioCryst; that BioCryst may not be able to retain its current pharmaceutical and biotechnology partners for further development of its product candidates or it may not reach favorable agreements with potential pharmaceutical and biotechnology partners for further development of its product candidates; that our actual cash burn rate may not be consistent with our expectations; that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products a
'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. BioCrysts Partner Shionogi Launches Peramivir In Japan Under The Name RAPIACTA
2. BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors
3. BioCryst Announces Pricing of Public Offering of Common Stock
4. BioCryst to Present at Oppenheimer Healthcare Conference
5. Emergency Use Authorization Granted For BioCrysts Peramivir
6. BioCryst to Present at JMP Securities Healthcare Conference
7. BioCryst Clarifies Government Declaration Regarding Peramivir
8. BioCryst Provides Update Regarding Peramivir for Influenza
9. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
10. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
11. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...  Uroplasty, Inc. (NASDAQ: UPI ), a medical device ... to treat voiding dysfunctions, today reported financial results for ... Global revenue for the Company,s Urgent ®  PC ... quarterly revenue record, as compared to $3.9 million in ...
(Date:1/22/2015)... 22, 2015  Amgen (NASDAQ: AMGN ) today announced that ... results on Tuesday, Jan. 27, 2015, after the close of the ... call with the investment community at 2 p.m. PT. Participating in ... chairman and chief executive officer, and other members of Amgen,s senior ...
(Date:1/22/2015)... , Jan. 22, 2015 Increasing sophistication among enterprise ... of localization purchasing in 2015, says Moravia ... a recent study by market research firm Common Sense ... solution for their translation and localization needs. "From a ...
Breaking Medicine Technology:Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
... on Glucose Homeostasis Effects in,Normal and Diabetic Rats ... a 14-day,Phase IIa study of the safety profile ... selective inhibitor of,the Sodium-Glucose Transporter 2 (SGLT2) administered ... 2 diabetes, no,discontinuations due to adverse events and ...
... LOUISVILLE, Colo., June 26, 2007 /PRNewswire-FirstCall/ --,Replidyne, ... I trials,studying REP8839, a novel topical antibiotic ... major skin pathogens including,methicillin-resistant S. aureus (MRSA). ... that topically applied REP8839 appears safe,well-tolerated and ...
Cached Medicine Technology:First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 2First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 3First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 4First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 5First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 6Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 2Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 3Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 4
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the release ... for kids with cancer. The Chemo Duck App, available on iTunes ... enjoyable games to help children of all ages living with cancer ... keep kids entertained, educated and at ease while waiting for clinic ...
(Date:1/22/2015)... 2015 The Incredible Bulk is a revolutionary ... increase lean muscle by up to 30lbs in less than ... of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... step-by-step, scientific diet formula that allows the body to pack ...
(Date:1/22/2015)... 23, 2015 AngelWeddingDress, the premier women’s ... maternity wedding dresses. View website of AngelWeddingDress.com ... for maternity wedding dresses online for a bridal party. ... high quality for them. Its maternity wedding dresses are ...
(Date:1/22/2015)... A new white paper by The ... in the long-term care environment as well as provides ... The paper, “The Power of Person-Centeredness in Long-Term Care: ... of the patient, resident and family experience in long-term ...
(Date:1/22/2015)... Oceanside,CA (PRWEB) January 22, 2015 For over 20 ... the Oceanside and Vista area has treated just about ... other personal injury circumstances. And for those same twenty-plus years, ... victims of all those injuries with the best possible doctor. ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
... Available at ... PhillyHealthInfo.org, PHILADELPHIA, Oct. 9 PhillyHealthInfo is the ... Chester,Delaware, and Montgomery counties. Go to http://www.PhillyHealthInfo.org ,for this season,s flu ... Where to go for free or low cost flu shots. -- ...
... -- Nurses and physicians at Nationwide Childrens Hospital are using ... extreme pain of dressing changes and wound care. Instead ... Childrens Hospital Burn Center is now using virtual reality games ... wounds. , Its long been known that the ...
... Nurse Savvy Research Group is,an exciting newcomer ... an online medical information service established to,provide the ... which,doctors they would choose for a variety of ... data gathered for the website will be,obtained through ...
... 9, 2007 Chairman of the,Board and Chief Executive ... PG ) shareholders at its annual meeting today. ... the short, mid and long term,-- consistently, reliably and ... the company,s results for fiscal 2007. P&G increased,net sales ...
... UPCARE(R) E2E, an end-to-end, financial and clinical ... for laboratories. -- ... Mich., Oct. 9 Today, UPCARE Technology, Inc.,unveiled its new ... part on the success of its parent company, Marquette,General Health ...
... three scientists receiving the 2007 Nobel Prize for Physiology or ... their careers, bringing to 42 the number of Nobel Laureates ... Capecchi, Ph.D. of the University of Utah and Oliver Smithies, ... with Sir Martin J. Evans of Cardiff University in Wales ...
Cached Medicine News:Health News:Virtual game helps children escape realities of burn unit 2Health News:Nursesavvy.com Promoting Quality Healthcare for Everyone 2Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 2Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 3Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 4Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 5Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 6Health News:UPCARE Technology to Share the Secrets of its Parent's Success in Lab Outreach 2Health News:UPCARE Technology to Share the Secrets of its Parent's Success in Lab Outreach 3Health News:UPCARE Technology to Share the Secrets of its Parent's Success in Lab Outreach 4
The flexible EXXCEL ePTFE Vascular Access Graft material is designed to offer textile-like handling characteristics-cuts neatly for a clean edge, retains fully open lumen shape, and sutures smoothly....
... intended for monitoring the accuracy and precision of ... in vitro diagnostic use only. Provided in a ... up to ten days stability at 2 ... used in accordance with the directions accompanying the ...
PowerMed is a billing software....
Managed care is a billing and tracking system....
Medicine Products: